Journal of Ovarian Research最新文献

{"title":"Embryo utilisation rate and transferable embryo to oocyte ratio correlate positively with livebirth rate but negatively with oocyte number: analysis of 14,156 fresh IVF/ICSI cycles.","authors":"Adrija Kumar Datta, Geeta Nargund, Martin Wilding, Sam Dobson, Stuart Campbell","doi":"10.1186/s13048-025-01693-4","DOIUrl":"https://doi.org/10.1186/s13048-025-01693-4","url":null,"abstract":"<p><strong>Background: </strong>The live birth rates (LBRs) do not rise after a certain number of oocytes are collected in fresh IVF cycles. Although the detrimental effect of high ovarian response on the endometrium has been recognised, the effect of high oocyte yield on oocyte competency remains disputed. The purpose of this study was to examine whether high oocyte yield adversely affect the competency of oocytes or embryos. We retrospectively analysed UK's National database (published by Human Fertilisation and Embryology Authority (HFEA)- year 2015-2016) including couples who underwent first IVF treatment with single embryo transfer or had no available embryo, due to tubal or unexplained infertility among women aged < 40 years.</p><p><strong>Results: </strong>Retrospective analysis of 14,156 fresh IVF/ ICSI cycles that met the inclusion criteria revealed an inverse correlation between Embryo Utilisation Rate (EUR) and the oocyte yield (r= -0.250047, p < 0.0001). The Transferable Embryo to Oocyte Ratio (TEOR) also inversely correlated with the number of retrieved oocyte (r = - 0.331431, p < 0.0001). The number of oocytes that did not produce transferable embryos had a stronger positive correlation with oocyte yield (r = 0.916676, p < 0.0001) than those produced transferable embryos (r = 0.569972, p < 0.0001). Both EUR (p = 0.01) and TEOR (P < 0.0001) correlated positively with the live birth except in the women age-group of 38-39 years. Although fertilisation rates remained similar, both EUR and TEOR declined steadily with the increasing number of oocytes until it reached a nadir at around 8-9 oocytes. At this point the LBR in fresh cycles reached its peak.</p><p><strong>Conclusion: </strong>The EUR and TEOR decline with increasing oocyte yield while both the ratios have a positive correlation with live birth. Despite declining EUR and TEOR, increasing oocyte yield can still boost fresh cycle LBR until the proportions of transferable embryos fall to a nadir. Thus, the focus needs to be on finding more efficient method for embryo selection and avoid generating too many wasteful oocytes that only pose more risk or raise cost without improving fresh cycle LBR.</p><p><strong>Trial number: </strong>Being a retrospective study, prior registration of the trial was not required.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"112"},"PeriodicalIF":3.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA sequencing reveals the role of GTF2F2 in ovarian cancer oncogenesis and progression.","authors":"Haiyang Du, Gao Si, Jiqing Si, Xuejie Song, Fuchun Si","doi":"10.1186/s13048-025-01686-3","DOIUrl":"https://doi.org/10.1186/s13048-025-01686-3","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer is one of the most common malignancies of the female reproductive system and is associated with poor prognosis. This study aimed to utilize single-cell RNA sequencing to investigate the heterogeneity of malignant epithelial cells in ovarian cancer, focusing on their potential functions and the implications for treatment and prognosis.</p><p><strong>Methods: </strong>Single-cell RNA sequencing data were clustered using a single-cell transcriptome clustering method, and malignant epithelial cells were identified through copy number variation analysis. The interaction patterns between different malignant subpopulations and immune/stromal cells were analyzed using cell-to-cell communication analysis. A risk score (URS) model based on the UBE2C + epithelial subpopulation was then constructed through LASSO and multivariable Cox regression. High and low URS groups were compared in terms of tumor mutational burden (TMB), survival outcomes, and drug sensitivity. Finally, the role of GTF2F2 in ovarian cancer progression was validated through gene knockdown experiments in an ovarian cancer cell line (ES-2).</p><p><strong>Results: </strong>Three major malignant epithelial cell subpopulations were identified (TMSB4X + Epi, TSC22D1 + Epi, and UBE2C + Epi). The UBE2C + Epi subpopulation exhibited higher stemness and greater invasive potential. The constructed URS model effectively stratified patients into high- and low-risk groups, with the high-risk group displaying a higher TMB level (p = 0.00011). Drug sensitivity predictions indicated that osimertinib, rapamycin, and dihydrorotenone might have stronger inhibitory effects in the high-risk group, whereas ERK inhibitors were more effective in the low-risk group. Functional assays demonstrated that GTF2F2 knockdown significantly suppressed ovarian cancer cell migration and invasion. Western blot analyses further showed elevated E-cadherin and reduced N-cadherin expression, suggesting that GTF2F2 may promote epithelial-mesenchymal transition (EMT).</p><p><strong>Conclusion: </strong>The risk score model established in this study offers a novel framework for patient stratification and personalized therapy. Notably, the identification of the UBE2C + Epi subpopulation and key genes such as GTF2F2 highlights potential diagnostic and therapeutic targets, shedding light on the pathogenesis of ovarian cancer and paving the way for precision medicine approaches.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"114"},"PeriodicalIF":3.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients: a pilot randomized clinical trial.","authors":"Elnaz Salari, Negar Ajabi Ardehjani, Ladan Kashani, Kasra Jafari, Ashraf Moini","doi":"10.1186/s13048-025-01702-6","DOIUrl":"https://doi.org/10.1186/s13048-025-01702-6","url":null,"abstract":"<p><strong>Background: </strong>This study compared the effectiveness of cabergoline and hydroxychloroquine in preventing ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian stimulation.</p><p><strong>Materials and methods: </strong>This double-blind, parallel, and randomized clinical trial was performed from April to June 2024. Forty-two patients with PCOS who were candidates for assisted reproductive techniques were randomized into two groups. The first group received 0.5 mg of cabergoline, and the second group received 400 mg of hydroxychloroquine for 8 days. Then, ultrasounds were conducted on days 3 and 5 after oocyte retrieval to assess for OHSS.</p><p><strong>Results: </strong>Three and five days after oocyte retrieval, laboratory findings, and clinical outcomes were similar between the cabergoline and hydroxychloroquine groups. Key laboratory parameters, including hemoglobin, hematocrit, sodium, potassium, blood urea nitrogen, and creatinine, did not show significant differences between the groups. On day three, OHSS incidence didn't have a significant difference between the hydroxychloroquine and cabergoline groups, both for the mild (31.58% vs. 42.86%) and moderate (15.79% vs. 9.52%) groups. Mild cases were observed in one of the patients in both groups 5 days after pickup (p = 0.942). No patients in the cabergoline group required hospitalization or treatment, compared to one in the hydroxychloroquine group (p = 0.127).</p><p><strong>Conclusion: </strong>The incidence of OHSS was similar between cabergoline and hydroxychloroquine, with no significant differences observed in laboratory parameters or clinical outcomes after oocyte retrieval. However, given the study's sample size, further research is needed before these findings can be generalized to a larger population.</p><p><strong>Clinical trial number: </strong>http://www.irct.ir ; Registration number: IRCT20240305061171N1; Registration date: 2024 June 29.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"113"},"PeriodicalIF":3.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Beautiful and regular vascularization in a borderline ovarian seromucinous tumor detected by microvascular imaging.","authors":"Luying Gao, Mei Yu, Dan Wang, Na Su","doi":"10.1186/s13048-025-01699-y","DOIUrl":"https://doi.org/10.1186/s13048-025-01699-y","url":null,"abstract":"","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"111"},"PeriodicalIF":3.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study.","authors":"Yuta Endo, Yoshiaki Takagawa, Yuki Yoshimoto, Masanori Machida, Yuntao Dai, Yusuke Azami, Ichiro Seto, Kanako Takayama, Motohisa Suzuki, Tatsuhiko Nakasato, Yasuhiro Kikuchi, Takahiro Kato, Akiko Yamaguchi, Shu Soeda, Keiya Fujimori, Masao Murakami","doi":"10.1186/s13048-025-01695-2","DOIUrl":"https://doi.org/10.1186/s13048-025-01695-2","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have demonstrated the benefit of radiation therapy for patients with recurrent epithelial ovarian cancer; however, the effects of proton beam therapy in these patients remain unelucidated. This study aimed to evaluate the use of proton beam therapy in recurrent epithelial ovarian cancer and to identify factors predictive of local control.</p><p><strong>Results: </strong>This retrospective study included 13 patients with a total of 30 lesions who underwent proton beam therapy for recurrent epithelial ovarian cancer at our institution between October 2008 and March 2021. The median age of the patients at the initial proton beam therapy was 62 (range, 42-82) years. Eight patients had stage III or IV disease, and seven had serous carcinoma; ten patients exhibited platinum resistance. The irradiated sites included 16 lymph nodes and 9 pelvic or abdominal masses. The median tumor size and maximum standardized uptake value (SUVmax) of fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography (¹⁸F-FDG-PET/CT) were 25 (range, 9-83) mm and 12.6 (range, 3.9-25.1), respectively. The median total dose was 65 (range, 45-72) Gy (relative biological effectiveness). The 1- and 2-year local control were 91.5% and 71.3%, respectively. The SUVmax of ¹⁸F-FDG-PET/CT was a significant predictor of local control (cutoff value, 17.7). The median progressing-free and overall survival after proton beam therapy initiation were 9.6 and 21.5 months, respectively. No grade 3 or higher proton beam therapy-induced adverse events were observed.</p><p><strong>Conclusion: </strong>Proton beam therapy demonstrated excellent local control of recurrent epithelial ovarian cancer, with tolerable toxicity, suggesting that this modality may represent a promising treatment option. The SUVmax of ¹⁸F-FDG-PET/CT performed prior to proton beam therapy may serve as a predictor of local control.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"110"},"PeriodicalIF":3.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"a1-antitrypsin, a new biomarker of polycystic ovary syndrome by changing its expression and rhythm.","authors":"Na Li, Beilei Shen, Wei Cao, RouRou Chen, Rongbo He, Li Qian, Lin Xu, Yu Liu","doi":"10.1186/s13048-025-01698-z","DOIUrl":"10.1186/s13048-025-01698-z","url":null,"abstract":"<p><strong>Background: </strong>Previous proteomic studies have demonstrated the potential for identifying specific diagnostic biomarkers in the plasma and follicular fluid of patients with polycystic ovary syndrome (PCOS), which was utilized to elucidate the underlying etiology of PCOS. Our study aimed to identify differences in serum protein expression between newly diagnosed PCOS patients and healthy controls and to identify novel biomarkers for the diagnosis and treatment of women with PCOS. We focused on the association between a1-antitrypsin (A1AT) levels and hormonal-metabolic parameters in women with PCOS.</p><p><strong>Materials and methods: </strong>This study involved 70 newly diagnosed PCOS patients and 78 healthy controls. We measured serum A1AT levels via Label-free quantitative proteomics and ELISA methods. Additionally, blood samples from 10 PCOS patients and 10 healthy controls were collected over 24 h. Furthermore, we established a mouse model of PCOS to detect serum A1AT levels and the A1AT mRNA expressions of liver tissues. We also analyzed the mRNA expressions of several clock-related genes in the hypothalamus, pituitary, ovary and liver tissues.</p><p><strong>Results: </strong>Serum A1AT levels were higher in women with newly diagnosed PCOS than controls. Meanwhile, the levels of serum IL-6 and TNF-a in PCOS patients were higher than those of healthy controls. A1AT levels showed a positive correlation with luteinizing hormone (LH) and testosterone levels, whereas it showed a negative correlation with sex hormone-binding protein in women with PCOS. However, some metabolic markers were not significantly associated with the level of A1AT. Interestingly, serum A1AT level exhibited a significant diurnal rhythm in the control group expectedly, while it was not diurnal in the PCOS group. Animal studies suggest that the increase in A1AT levels observed in PCOS could be associated with alterations in the expression of clock-related genes in reproductive tissues.</p><p><strong>Conclusions: </strong>Increased A1AT levels in women with newly diagnosed PCOS were related to androgens, suggesting that A1AT might be a potential biomarker for PCOS. Serum A1AT levels exhibited a significant diurnal rhythm in the control group, while it was not diurnal in the PCOS group. These findings provide a theoretical foundation for understanding the role of the circadian clock in the prevention and treatment of PCOS in females with biorhythm disorders.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"109"},"PeriodicalIF":3.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network pharmacology and experimental validation to elucidate the mechanism of the treatment of polycystic ovary syndrome with insulin resistance by Resina Draconis.","authors":"Jing Wang, Yehao Luo, Yueting Liu, Xiusong Tang, Jianhui Gu, Zheng Huang, Ting Lv, Jun Luo, Gang Fang","doi":"10.1186/s13048-025-01685-4","DOIUrl":"10.1186/s13048-025-01685-4","url":null,"abstract":"<p><strong>Background: </strong>Resina Draconis(RD) is a traditional Chinese medicine that activates blood circulation and removes blood stasis. Modern pharmacological studies have proved that RD has hypoglycaemic, pancreatic islets-protective, oestrogenic activity, anti-inflammatory, antibacterial and anti-tumour effects. Studies have shown that insulin resistance (IR) is the core pathological mechanism of polycystic ovary syndrome (PCOS), and RD can lower blood glucose to ameliorate IR, which has achieved significant results in the treatment of diabetes. However, the mechanism of action of RD in the treatment of PCOS-IR is still unclear.</p><p><strong>Methods: </strong>Network pharmacology analysis was used to predict the potential therapeutic targets of the active ingredients of RD. Experimental validation used a rat model of insulin resistance in PCOS; PCOS-IR symptoms were assessed, ovarian pathology was evaluated, and serum levels of insulin and sex hormones were determined. Expression levels of the PI3K, p-PI3K, Akt, p-Akt, GLUT4, FOXO3a, and P27 proteins were also measured in rat ovaries, along with mRNA expression levels of PI3K, Akt, GLUT4, FOXO3a, and P27.</p><p><strong>Results: </strong>Network pharmacological analyses indicated that the PI3K/Akt signalling pathway may play an important role in the treatment of PCOS-IR rats with RD. Experiments in PCOS-IR rats showed that RD significantly reversed insulin resistance, improved pathological changes in the ovaries, increased serum levels of follicle stimulating hormone (FSH) and estradiol (E2), and decreased levels of luteinizing hormone (LH), testosterone (T) and insulin. In addition, RD increased the levels of PI3K, p-PI3K, Akt, p-Akt and GLUT4, and decreased the levels of FOXO3a and P27 in the ovarian tissues of PCOS-IR rats, suggesting that RD may improve the symptoms of PCOS-IR in rats through the PI3K/Akt signalling pathway.</p><p><strong>Conclusion: </strong>RD might improve insulin resistance and ovarian function in PCOS-IR by upregulating PI3K, p-PI3K, Akt, p-Akt and GLUT4 expression and downregulating FOXO3a and P27, thereby activating the PI3K/Akt signaling pathway. RD also regulated the LH/FSH ratio, increased E2 levels, reduced LH and T levels, and alleviated PCOS-IR symptoms in a rat PCOS-IR model.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"108"},"PeriodicalIF":3.8,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging roles of N6-methyladenosine (m6A) deregulation in polycystic ovary syndrome.","authors":"Leyi Jiang, Jiaying Xiao, Liangzhen Xie, Feifei Zheng, Fangliang Ge, Xue Zhao, Ruonan Qiang, Jie Fang, Zhinan Liu, Zihan Xu, Ran Chen, Dayong Wang, Yanfeng Liu, Qing Xia","doi":"10.1186/s13048-025-01690-7","DOIUrl":"10.1186/s13048-025-01690-7","url":null,"abstract":"<p><p>Polycystic ovary syndrome (PCOS) is an endocrine metabolic syndrome characterized by ovulation disorders, hyperandrogenemia, and polycystic ovaries, which seriously affect the psychological and physical health of childbearing women. N6-methyladenosine (m6A), as the most common mRNA epigenetic modification in eukaryotes, is vital for developing the female reproductive system and reproductive diseases. In recent years, an increasing number of studies have revealed the mechanisms by which m6A modifications and their related proteins are promoting the development of PCOS, including writers, erasers and readers. In this work, we reviewed the research progress of m6A in the pathophysiological development of PCOS from the starting point of PCOS clinical features, included the recent studies or those with significant findings related to m6A and PCOS, summarized the current commonly used therapeutic methods in PCOS and the possible targeted therapies against the m6A mechanism, and looked forward to future research directions of m6A in PCOS. With the gradual revelation of the m6A mechanism, m6A and its related proteins are expected to become a great field for PCOS treatment.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"107"},"PeriodicalIF":3.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generation of healthy bovine ovarian organoids: a proof-of-concept derivation technique.","authors":"María Gómez-Álvarez, Marcos Agustina-Hernández, Emilio Francés-Herrero, Clara Bueno-Fernandez, Paula Alonso-Frías, Nadaya Corpas, Amparo Faus, Antonio Pellicer, Irene Cervelló","doi":"10.1186/s13048-025-01673-8","DOIUrl":"10.1186/s13048-025-01673-8","url":null,"abstract":"<p><strong>Background: </strong>Organoids have emerged as powerful tools in reproductive medicine and bioengineering, offering three-dimensional (3D) models that closely mimic native tissues. However, the development of protocols for generating healthy epithelial ovarian organoids (OvaOs) remains significantly underexplored, as most studies focus on ovarian cancer models. This work presents an effective protocol for generating healthy bovine OvaOs as a physiological and translational model for ovarian research, mimicking the anatomical and functional similarities between bovine and human ovarian surface epithelium (OSE).</p><p><strong>Results: </strong>Healthy bovine OvaOs were successfully derived using a mechanical-enzymatic method with a predominant mechanical approach, which proved superior to exclusively enzymatic techniques that failed to yield an adequate number of OSE cells. The biological potential of the resulting OvaOs to establish long-term organoid lines was demonstrated by their exponential growth over a 21-day culture period, extensive passaging capacity, and high viability after freeze-thaw cycles. Histological analyses confirmed that healthy bovine OvaOs recapitulated OSE tissue characteristics, including the expression of Cytokeratin 18, Vimentin, and CD44, while the absence of Paired box gene-8 (PAX8) expression excluded contamination by fimbrial cells.</p><p><strong>Conclusions: </strong>This study describes an effective mechanical protocol for deriving healthy OvaOs from bovine ovaries. These 3D models faithfully replicate the biological features of bovine OSE, with sustained viability across long-term cultures, passaging, and freeze-thaw cycles. These findings underscore their potential as translational models for advancing ovarian physiology research and adapting protocols to human ovarian tissue.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"106"},"PeriodicalIF":3.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota and ovarian diseases: a new therapeutic perspective.","authors":"Shan Ju, Zhen Yang Kang, Li Ya Yang, Yong Jun Xia, Yi Ming Guo, Sui Li, Hongli Yan, Ming Kang Qi, Hui Ping Wang, Lian Zhong","doi":"10.1186/s13048-025-01684-5","DOIUrl":"10.1186/s13048-025-01684-5","url":null,"abstract":"<p><p>The gut microbiota is a complex community of microorganisms that inhabit the human gastrointestinal tract, helping to maintain the ecological balance of the body's internal and external environments. Disruptions in the composition and diversity of gut microbiota, as well as changes in their metabolic functions, can link to the development and severity of conditions such as premature ovarian insufficiency, polycystic ovary syndrome, and ovarian tumors. This article thoroughly reviews recent research on the connection between gut microbiota and ovarian diseases, providing fresh perspectives on their prevention, pathogenesis, and treatment.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"105"},"PeriodicalIF":3.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}